

44. (Reiterated) The method of claim 42 wherein the tumor or cancer is a colorectal tumor.
45. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a prostate tumor.
46. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a pancreatic tumor.
47. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a vulval tumor.
48. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a thyroid tumor.
49. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a hepatic tumor.
50. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a sarcoma.
51. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a glioblastoma.
52. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a head and neck tumor.
53. (Withdrawn) The method of claim 42 wherein the tumor or cancer is leukemia.
54. (Withdrawn) The method of claim 42 wherein the tumor or cancer is a lymphoid malignancy.

C2 55. (Amended) The method of claim 42 wherein the anti-ErbB2 antibody binds to an ErbB2 epitope bound by antibody 4D5 (ATCC CRL 10463).

56. (Amended) The method of claim 42 wherein the anti-ErbB2 antibody binds to an ErbB2 epitope bound by antibody 7C2 (ATCC HB-12215) or

antibody 7F3 (ATCC HB-12216).

Please cancel claims 59-62 without prejudice or disclaimer.

C3 63. (Amended) A method of treating a tumor or cancer characterized by overexpression or activation of ErbB2 comprising a first therapeutic regimen comprising administering an anti-ErbB2 antibody to a patient in an amount to kill or inhibit growth of tumor cells in the patient and a second therapeutic regimen comprising administering Vinorelbine in an amount to inhibit growth of tumor cells in the patient.

Please cancel claim 64 without prejudice or disclaimer.

C4 65. (Amended) The method of claim 63 wherein the anti-ErbB2 antibody binds to an ErbB2 epitope bound by antibody 4D5 (ATCC CRL 10463).

66. (Amended) The method of claim 63 wherein the anti-ErbB2 antibody binds to an ErbB2 epitope bound by antibody 7C2 (ATCC HB-12215) or antibody 7F3 (ATCC HB-12216).

Please cancel claims 67-68 without prejudice or disclaimer.